MISSISSAUGA, Ontario, May 02, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX^® is the #1 recommended iron supplement brand in Canada, based on a national survey of Canadian pharmacists and physicians⁽¹⁾. This is the eighth consecutive year that FeraMAX^® has been awarded this vote of confidence.

The annual Survey on OTC Counselling and Recommendations is an important pharmaceutical industry indicator which tracks pharmacist and physician counselling patterns for over-the-counter (OTC) products in Canada. The survey was fielded between October 2022 and January 2023 by EnsembleIQ Research and Innovation: Pharmacy Practice + Business, The Medical Post, Profession Santé, CanadianHealthcareNetwork.ca, and ProfessionSanté.ca. This is the only national survey to research the role of Canadian pharmacists and physicians as counsellors and advisors in non-prescription products.

“We thank Canadian physicians and pharmacists for their growing trust and confidence in the FeraMAX^® brand for eight years in a row,” commented René Goehrum, President and CEO of BioSyent. “Healthcare professionals are essential in supporting the iron health of Canadians and BioSyent continues to provide innovative solutions, supportive continuing education, and patient-focused resources to our healthcare partners.”

About FeraMAX^®

The FeraMAX^® Pd brand has a unique, patented Polydextrose-Iron Complex (PDIC) formulation and all versions of FeraMAX^® are dosed once daily, supporting iron health with treatment, maintenance and preventative supplements. FeraMAX^® Pd Therapeutic 150 is an oral iron supplement indicated for the treatment of iron deficiency anemia. FeraMAX^® Pd Powder 15 makes iron therapy convenient for children. On March 7^th 2023, BioSyent announced an important addition to the FeraMAX^® family of iron supplements with FeraMAX^® Pd Maintenance 45 designed to prevent iron deficiency, maintain healthy iron levels, and to address a gap in iron health therapy. The FeraMAX^® family represents innovative solutions to support iron health across various life stages.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty, and international business units.

As of the date of this press release, the Company has 12,091,919 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 905-206-0013
Web: www.biosyent.com

1. Reference for ranking:
   
   Pharmacy Practice + Business, The Medical Post and Profession Santé 2023 Survey on OTC Counselling and Recommendations.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.